Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PacificGMP to use perfusion process to produce AGT-190, under cGMP standards
Subscribe to our email newsletter
ArmaGen Technologies has selected PacificGMP to produce its proprietary protein for a phase 1 clinical trial. Under the agreement, PacificGMP will use a perfusion process to produce the antibody fusion protein, AGT-190, under cGMP (current good manufacturing practices) standards. Additionally, PacificGMP is expected to perform cGMP cell bank development.
Leigh Pierce, president and CSO of PacificGMP, said: “We are delighted to have been selected by ArmaGen to produce their human clinical trial material. ArmaGen’s technology shows progress in a vital area of therapeutic development. We at PacificGMP are excited to be an important part of ArmaGen’s team for this project.”
William Pardridge, chairman of ArmaGen, said: “PacificGMP brings considerable expertise in GMP manufacturing and in perfusion bioprocessing. We are pleased to have PacificGMP manufacture AGT-190 and generate our Master Cell Bank, to support our stroke and Parkinson’s disease clinical program.”